Vestibulotoxicity in consequence of tobramycin therapy in cystic fibrosis patients
Phase 4
Recruiting
- Conditions
- damage of the inner eardisturbance of equilibrium10022396
- Registration Number
- NL-OMON29992
- Lead Sponsor
- HagaZiekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
cystic fibrosis patients currently known in the HAGA hospital who have been treated at least one time with intravenous tobramycin and with an audiogram in medical dossier
Exclusion Criteria
patients treated with other intravenous aminoglycoside therapy than tobramycine
patients receiving intravenous aminoglycosides during investigation.
patients with perforation of one of the tympanic membranes.
patients with a radical cave.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary study parameter is formulated as whether there is damage to the<br /><br>vestibulum or there is not. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secundary study parameter is formulated as whether there is disturbance of<br /><br>equilibrium due to damage of the vestibulum or there is not.</p><br>